Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.

Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

Septerna, Inc. (NASDAQ:SEPN), operating within the biotechnology space, continues to attract attention amid notable activity ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

Shares of Septerna, Inc. (SEPN) have gained 57.8% over the past four weeks to close the last trading session at $9.42, but there could still be a solid upside left in the stock if short-term price ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments.

The analysis of recent analyst actions sheds light on the perception of Septerna by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 diabetes, obesity and other cardiometabolic diseases. The exclusive global ...

May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates ...

May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business ...

May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business ...